Novel luminescence assay offers new possibilities for the risk assessment of silica nanoparticles

Nanotoxicology

Volumn 2, Issue 4, 2008, Pages 243-251

  Wahl, Birgit ^a   Daum, Nicole ^a   Ohrem, Hans Leonhard ^b   Lehr, Claus Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

Cytotoxicity; LDH assay; Luminescence assay; Nanoparticles; Silica

Indexed keywords

LACTATE DEHYDROGENASE; NANOPARTICLE; SILICON DIOXIDE;

ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ASSAY; HUMAN; HUMAN CELL; LUMINESCENCE; PARTICLE SIZE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 57349092512     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.1080/17435390802513204     Document Type: Article

References (36)

1. Ahlin P, Kristl J, Kristl A, Vrecer F. 2002. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm 239(1-2):113-120.
2. Allemann E, Leroux J, Gurny R. 1998. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 34(2-3):171-189.
3. Artursson P, Borchardt RT. 1997. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm Res 14(12):1655-1658.
4. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46(1-3):27-43.
5. Balamurugan B, Toshiro M. 2006. Inhomogeneous effect of particle size on core-level and valence-band electrons: Size-dependent electronic structure of Cu[sub 3]N nanoparticles. Applied Physics Letters 89(3):033112-3.
6. Borenfreund E, Puerner JA. 1985. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24(2-3):119-124.
7. Chiu IS. 2004. A study of the size effect on the temperature-dependent resistivity of bismuth nanowires with rectangular cross-sections. Nanotechnology 15:1489-1492.
8. Chong HS, Garmestani K, Bryant LH Jr, Milenic DE, Overstreet T, Birch N, Le T, Brady ED, Brechbiel MW. 2006. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging. J Med Chem 49(6):2055-2062.
9. Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, Mou CY, Chen YC, Huang DM. 2007. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 28(19):2959-2966.
10. Crouch SP. 2000. Biocompatibility testing using ATP bioluminescence. Med Device Technol 11(8):12-15.
11. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. 1993. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 160(1):81-88.
12. Evonik. 2007. Aerosil(R) 200 hydrophilic fumed silica.
13. Evonik. 2008. Aerosil(R) 200 safety data sheet.
14. Fogh J, Fogh JM, Orfeo T. 1977. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59(1):221-226.
15. Frgala T, Kalous O, Proffitt RT, Reynolds CP. 2007. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 6(3):886-897.
16. Gratzner HG. 1982. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 218(4571):474-475.
17. Hansen SF, Michelson ES, Kamper A, Borling P, Stuer-Lauridsen F, Baun A. 2008. Categorization framework to aid exposure assessment of nanomaterials in consumer products. Ecotoxicology 17(5):438-447.
18. Heikkila T, Salonen J, Tuura J, Hamdy MS, Mul G, Kumar N, Salmi T, Murzin DY, Laitinen L, Kaukonen AM, et al. 2007a. Mesoporous silica material TUD-1 as a drug delivery system. Int J Pharm 331(1):133-138.
19. Heikkila T, Salonen J, Tuura J, Kumar N, Salmi T, Murzin DY, Hamdy MS, Mul G, Laitinen L, Kaukonen AM, et al. 2007b. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 14(6):337-347.
20. Herzog E, Casey A, Lyng FM, Chambers G, Byrne HJ, Davoren M. 2007. A new approach to the toxicity testing of carbon-based nanomaterials - the clonogenic assay. Toxicol Lett 174(1-3):49-60.
21. Ito A, Shinkai M, Honda H, Kobayashi T. 2005. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng 100(1):1-11.
22. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR Jr. 2005. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65(12):5317-5324.
23. Laaksonen T, Santos H, Vihola H, Salonen J, Riikonen J, Heikkila T, Peltonen L, Kumar N, Murzin DY, Lehto VP, et al. 2007. Failure of MTT as a toxicity testing agent for mesoporous silicon microparticles. Chem Res Toxicol, 20(12):1913-8.
24. Malich G, Markovic B, Winder C. 1997. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124(3):179-192.
25. Maynard AD. 2007. Nanotechnology: The next big thing, or much ado about nothing? Ann Occup Hyg 51(1):1-12.
26. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2):55-63.
27. Nel A, Xia T, Madler L, Li N. 2006. Toxic potential of materials at the nanolevel. Science 311(5761):622-627.
28. Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, et al. 2005a. Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Part Fibre Toxicol 2:8.
29. Oberdörster G, Oberdörster E, Oberdörster J. 2005b. Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113(7):823-839.
30. Salonen J, Laitinen L, Kaukonen AM, Tuura J, Bjorkqvist M, Heikkila T, Vaha-Heikkila K, Hirvonen J, Lehto VP. 2005. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 108(2-3):362-374.
31. Scientific Committee on Consumer Products (SCCP), European Commission. 2007. SCCP SCoCP. Safety of nanomaterials on cosmetic products. 18 December 2007.
32. Schulze C, Kroll A, Lehr C-M, Schäfer UF, Becker K, Schnekenburger J, Schulze Isfort C, Landsiedel R, Wohlleben W. 2008. Not ready to use - overcoming pitfalls when dispersing nanoparticles in physiological media. Nanotoxicology 2(2):51-61.
33. Ulukaya E, Ozdikicioglu F, Oral AY, Demirci M. 2008. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro 22(1):232-239.
34. Wang Z, Li J, Liu B, Hu J, Yao X, Li J. 2005. Chemiluminescence of CdTe nanocrystals induced by direct chemical oxidation and its size-dependent and surfactant-sensitized effect. J Phys Chem B 109(49):23304-23311.
35. Weyermann J, Lochmann D, Zimmer A. 2005. A practical note on the use of cytotoxicity assays. Int J Pharm 288(2):369-376.
36. Worle-Knirsch JM, Pulskamp K, Krug HF. 2006. Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett 6(6):1261-1268.